How did SANA's R&D expenses shift in Q3 2024?
5/9/2025 04:26am
Sana Biotechnology (SANA) experienced a significant increase in R&D expenses in Q3 2024, with the company reporting $47.71 million in R&D spending for the period ending Q3 2024. This represents a substantial investment in research and development, indicating the company's commitment to advancing its technological capabilities and product pipeline.
|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|SANA|SANA.O|Sana Biotechnology|2023 Q4|6.9835E7|19.443446730634374|185|
|SANA|SANA.O|Sana Biotechnology|2024 Q1|9.4455E7|40.37838480516006|185|
|SANA|SANA.O|Sana Biotechnology|2024 Q2|3.293E7|-66.97853052956691|185|
|SANA|SANA.O|Sana Biotechnology|2024 Q3|4.7709E7|380.6081637454417|185|